ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1770

All-Cause Mortality For Patients with Rheumatoid Arthritis In a Universal Public Health Care System

Jessica Widdifield1,2, J. Michael Paterson1, Sasha Bernatsky3, Bindee Kuriya4, J. Carter Thorne5, Simon Hollands1 and Claire Bombardier6, 1Institute for Clinical Evaluative Sciences, Toronto, ON, Canada, 2University of Toronto, Toronto, ON, Canada, 3McGill University, Montreal, QC, Canada, 4Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, 5Southlake Regional Health Centre, Newmarket, ON, Canada, 6Rheumatology, University of Toronto, Toronto, ON, Canada

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: morbidity and mortality and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Title: Epidemiology and Health Services Research III: Healthcare Costs and Mortality in Rheumatic Disease

Session Type: Abstract Submissions (ACR)

Background/Purpose: Studies evaluating trends in rheumatoid arthritis (RA) mortality over time have produced inconsistent results. Our aim was to estimate all-cause mortality in RA between 1996-2009, assess changes in mortality over time, and to compare mortality rates in RA with the general population.

Methods: We studied all residents in Ontario, Canada’s most populous province (N~13 million). Patients with RA were identified using the Ontario RA administrative Database (ORAD), a population-based research cohort generated from administrative data using a validated RA case definition. Linking to vital statistics data, we estimated annual all-cause mortality in RA by dividing the number of deaths among RA patients by the number of RA patients in each year. To compare mortality rates over time, we standardized for age and sex using the 2001 Ontario census population estimates. Age specific and age-and-sex standardized all-cause mortality estimates are expressed as the number of deaths per 1,000 RA patients for each year of the study period. The age-and-sex-standardized all-cause mortality estimates were compared in terms of relative percentage change between 1996 and 2008. We compared changes in mortality over time in RA patients, to estimates of mortality in the general population, over the same period. Finally, standardized mortality ratios (SMRs) were calculated, which provides the ratio of the mortality rate in RA patients versus the age and sex matched general population mortality.

Results: Age-and-sex standardized all-cause mortality ranged from 13.0 deaths per 1,000 RA patients (95%CI 12.2,13.9) in 1996 to 9.2 deaths per 1,000 RA patients (95%CI 8.4,10.0) in 2010. In 2008, the age-standardized rate for RA females was 8.8 deaths per 1,000 (95%CI 8.0,9.6) compared to 12.1 deaths per 1,000 (95%CI 10.3,14.2) in males, and rates were higher among males than females in all age groups. Age-specific all-cause mortality in RA patients increased with increasing age. Comparing RA mortality trends to the general population (Figure), since 1996, all-cause mortality decreased for RA by a relative 21.4%, with a smaller decrease (13.4%) in the general population. The SMRs for RA patients in 2000, 2004, and 2008 were 1.50 (95% CI 1.43-1.57), 1.43 (95%CI 1.37-1.50), and 1.41 (95%CI 1.35,1.47) respectively.

Conclusion: All-cause mortality for patients with RA has decreased over the past decade but remains elevated compared to the general population. Our results suggest 40-50% more deaths among RA patients compared to the general population. SMR estimates over the past decade do suggest the mortality gap may be slowly narrowing.


Disclosure:

J. Widdifield,
None;

J. M. Paterson,
None;

S. Bernatsky,
None;

B. Kuriya,
None;

J. C. Thorne,
None;

S. Hollands,
None;

C. Bombardier,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/all-cause-mortality-for-patients-with-rheumatoid-arthritis-in-a-universal-public-health-care-system/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology